Enabling Clinical Trial Innovation Through Ai Regulation At Fda

AI in Clinical Trials: FDA Prioritizes Adoption

New Techniques and Approaches

Artificial intelligence (AI), including machine learning, is gaining momentum in clinical research, transforming clinical trials from study design to patient recruitment.

FDA's Initiative

Resource Limitations

The Food and Drug Administration (FDA) acknowledges its resource limitations, leading to the unintentional prioritization of specific programs.

AIML's Role

The FDA believes that AI, including machine learning (AIML), will significantly advance drug development. The agency aims to develop and adopt these technologies.

Center for Clinical Trial Innovation

The FDA's newly established Center for Clinical Trial Innovation aims to promote the adoption of innovative technologies, including AI, in clinical trials.